Probiotic NVP-1703 Alleviates Allergic Rhinitis by Inducing IL-10 Expression: A Four-week Clinical Trial

Although several recent studies reported that probiotics might be beneficial for allergic rhinitis (AR), the effect of probiotics on AR is not consistent and have not been reproduced between studies. We aimed to determine the efficacy and safety of probiotic NVP-1703, a mixture of and , in subjects...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2020-05, Vol.12 (5), p.1427
Main Authors: Kang, Min-Gyu, Han, Seung-Won, Kang, Hye-Ryun, Hong, Seok-Jin, Kim, Dong-Hyun, Choi, Jeong-Hee
Format: Article
Language:English
Subjects:
Adult
Aged
Allergens
Allergic rhinitis
Allergies
Bifidobacterium longum
Clinical trials
Cytokines
Double-Blind Method
Female
Histamine
Hospitals
Humans
Immunoglobulin E
Immunology
Immunotherapy
Inflammation
Interleukin 10
Interleukin 13
Interleukin 4
Interleukin-10 - blood
Lactobacillus plantarum
Leukocytes (eosinophilic)
Male
Middle Aged
Probiotics
Probiotics - therapeutic use
Quality of life
Rhinitis
Rhinitis, Allergic, Perennial - blood
Rhinitis, Allergic, Perennial - microbiology
Rhinitis, Allergic, Perennial - therapy
Skin
Treatment Outcome
Tumor necrosis factor-TNF
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although several recent studies reported that probiotics might be beneficial for allergic rhinitis (AR), the effect of probiotics on AR is not consistent and have not been reproduced between studies. We aimed to determine the efficacy and safety of probiotic NVP-1703, a mixture of and , in subjects with perennial AR. Adult subjects with perennial AR received either NVP-1703 ( = 47) or placebo ( = 48) for four weeks. Total nasal symptom scores (TNSS), rhinitis control assessment test (RCAT), blood eosinophil count, allergen-specific IgE, and immunological parameters in serum and urine were compared at baseline and after four weeks. TNSS changes from baseline at weeks 1, 3, and 4 were significant between the NVP-1703 and placebo groups ( = 0.033, 0.031, and 0.029, respectively). RCAT score showed significant differences between the NVP-1703 and placebo groups ( = 0.049) at week 4. -specific IgE levels and serum IL-10 levels were significantly different between the NVP-1703 and placebo groups ( = 0.033 and = 0.047, respectively). IL-10/IL-4 and IL-10/IL-13 ratios were different between the NVP-1703 and placebo groups at week 4 ( = 0.046 and 0.018, respectively). NVP-1703 treatment reduced urinary prostaglandin F and leukotriene E levels ( > 0.05). Therefore, NVP-1703 can be treatment option for perennial AR.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu12051427